Whalesbook
Bhai log, ek common mistake karte hain investors! Sochte hain patent hai toh product bech hi sakte hain. Lekin reality mein, patent sirf dusron ko rokne ka right deta hai, khud product banane ka guarantee nahi. Pharma aur Tech sectors mein ye difference investors ke liye bada financial risk ban sakta hai.
Kya chal raha hai?
Market mein ek bada confusion hai patents ko lekar. Zyadatar log sochte hain ki agar company ko patent mil gaya, toh woh product freely manufacture aur sell kar sakte hain. Par Indian Patents Act, 1970 ke according, patent aapko sirf 'exclusionary right' deta hai. Matlab, aap dusron ko aapki invention use karne se rok sakte ho. Lekin, iska matlab yeh bilkul nahi ki aap khud koi aur ke existing patent ko infringe kiye bina product sell kar sakte ho.
Investors ke liye yeh kyun important hai?
Patent hold karne aur product sell karne ka right alag hona, investors ke liye risk management ka ek crucial point hai. Agar company 'Freedom-to-Operate' (FTO) check kiye bina koi product launch kar deti hai, toh woh anjaane mein kisi competitor ke patent ko violate kar sakti hai. Isse costly lawsuits, court injunctions, aur product ko market se hatana pad sakta hai. Yeh sab cheezein company ke revenue, profit margins, aur reputation ko seriously damage kar sakti hain.
Regulatory Approval vs. Patent Clearance ka difference
Investors ko yeh samajhna bohot zaroori hai ki regulatory approval aur patent clearance ek cheez nahi hai. Jaise ki pharma sector mein, company ko CDSCO se drug sell karne ka approval mil gaya, par iska matlab yeh nahi ki product patent issues se free hai. India mein 'patent linkage' system nahi hai, jahan government regulatory approval dene se pehle patent conflicts check kare. Toh, company ki responsibility hai ki woh ensure kare ki unka drug kisi third-party patent ko violate na kare.
Legal Battles ka risk
Legal risk ko aksar underestimate kiya jata hai jab tak woh balance sheet par dikhai na de. Jab kisi company par patent infringement ka ilzaam lagta hai, toh court case lamba aur mehenga ho sakta hai. Agar Indian court ne decide kiya ki company kisi competitor ki invention ko 'pith and marrow' se infringe kar rahi hai, toh operations band ho sakte hain. Isse 'execution risk' paida hota hai, jahan business projections, product timelines, aur manufacturing capacity par kiya gaya capital kharch waste ho sakta hai agar product market se hata diya jaye.
Investors ko kya track karna chahiye?
Investors ko companies ke legal aur intellectual property (IP) risks ko manage karne ke tarike par nazar rakhni chahiye. Achhi tarike se manage karne wali company typically FTO assessment karti hai koi bhi naye product launch mein bada paisa lagane se pehle. Investors company ki annual reports ya management ke commentary mein pending litigation, potential infringement risks, ya licensing agreements ke baare mein disclosures dekh sakte hain. Agar company ka history 'designing around' patents ka hai (matlab, woh competitors ke patents ko avoid karne ke liye unique solutions develop karte hain), toh yeh legal risk ko manage karne ka ek mature approach ho sakta hai. Iss sab due diligence ki kami company ko sudden aur unpredictable legal costs ke liye vulnerable bana sakti hai.